Dalpiciclib

Dalpiciclib

Clinical data
Other names	SHR6390
Identifiers
IUPAC name 6-Acetyl-8-cyclopentyl-5-methyl-2-[(5-piperidin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
CAS Number	1637781-04-4
PubChem CID	86279927
IUPHAR/BPS	11189
DrugBank	DB17456
ChemSpider	114951729
UNII	5ZHA5P4PFX
ChEMBL	ChEMBL4802161
Chemical and physical data
Formula	C25H30N6O2
Molar mass	446.555 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)C4CCNCC4)C5CCCC5)C(=O)C
InChI InChI=1S/C25H30N6O2/c1-15-20-14-28-25(29-21-8-7-18(13-27-21)17-9-11-26-12-10-17)30-23(20)31(19-5-3-4-6-19)24(33)22(15)16(2)32/h7-8,13-14,17,19,26H,3-6,9-12H2,1-2H3,(H,27,28,29,30) Key:SGJLSPUSUBJWHO-UHFFFAOYSA-N

Dalpiciclib is a drug for the treatment of various forms of cancer.^[1]

In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy.^[2]

Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.^[3]

1. ^ Chen X, Shen K (June 2023). "Dalpiciclib in advanced breast cancer". The Lancet. Oncology. 24 (6): 578–579. doi:10.1016/S1470-2045(23)00228-0. PMID 37269836.
2. ^ "Dalpiciclib in Combination with Letrozole or Anastrozole Significantly Improved Progression-free Survival in Systemic Treatment-naive, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer". hengrui.com.
3. ^ Sheikh MS, Satti SA (2021). "The emerging CDK4/6 inhibitor for breast cancer treatment". Molecular and Cellular Pharmacology. 13 (3): 9–12. PMC 8896653. PMID 35251463.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e